ACAN and juvenile idiopathic arthritis: The pattern observed in our cohort—elevated aggrecan levels in children with untreated JIA, stability during the first 18 months of etanercept treatment, followed by a sharp and significant increase after 24 months—is consistent with a two-phase model of cartilage response.